Stay updated on Phase 2 Study of CPI-0610 Combo in Myelofibrosis Clinical Trial
Sign up to get notified when there's something new on the Phase 2 Study of CPI-0610 Combo in Myelofibrosis Clinical Trial page.

Latest updates to the Phase 2 Study of CPI-0610 Combo in Myelofibrosis Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedNew Phase 1/2 CPI-0610 study with and without ruxolitinib added, broader MF/MPN trial scope, expanded criteria and sites, plus IPD data-sharing plan. Previous MF-only Phase 2 study and several location listings were removed.SummaryDifference100%
- Check16 days agoChange DetectedKey changes: added a broad operating-status notice and an updated version tag (v3.2.0); removed the specific medical term ‘Essential thrombocythemia’ and the older version tag v3.1.0.SummaryDifference3%
- Check24 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0.SummaryDifference0.1%
- Check31 days agoChange DetectedNo significant changes detected.SummaryDifference0.3%
- Check38 days agoChange DetectedThe page has been updated to Revision: v3.0.2, replacing v3.0.1, indicating an update to the content. The Back to Top element was removed, a minor UI change.SummaryDifference0.4%
- Check45 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.4%
Stay in the know with updates to Phase 2 Study of CPI-0610 Combo in Myelofibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 2 Study of CPI-0610 Combo in Myelofibrosis Clinical Trial page.